HRSA’s ‘Piecemeal’ Approach To 340B Integrity Rules Draws Manufacturer Objections
This article was originally published in The Pink Sheet Daily
Manufacturers say they might be penalized for violating program requirements that are yet to be established, since HRSA is issuing penalties rule first.
You may also be interested in...
Proposed rule would implement how civil monetary penalties will be applied to manufacturers that “knowingly and intentionally” deny 340B prices to eligible health care providers.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.